Skip to main content
. 2014 Sep 26;66(10):2675–2684. doi: 10.1002/art.38745

Figure 2.

Figure 2

Kaplan-Meier curves depicting time to herpes zoster (HZ) development within the phase III tofacitinib studies, by treatment group. Note that the placebo-treated patients were advanced to the tofacitinib dosage groups of 5 mg or 10 mg twice daily (BID) at 3 months or 6 months during these trials. The numbers of patients in each treatment group are shown below each time point.